---
firstreceived_date: November 5, 2014
is_fda_regulated: 'No'
reference:
- PMID: '15117830'
  citation: 'Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex:
    signaling strength and integrity for the sarcolemma. Circ Res. 2004 Apr 30;94(8):1023-31.
    Review.'
- PMID: '9891887'
  citation: Miller JB, Schaefer L, Dominov JA. Seeking muscle stem cells. Curr Top
    Dev Biol. 1999;43:191-219. Review.
- PMID: '21784508'
  citation: 'Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony
    K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub
    V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F. Exon skipping
    and dystrophin restoration in patients with Duchenne muscular dystrophy after
    systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase
    2, dose-escalation study. Lancet. 2011 Aug 13;378(9791):595-605. doi: 10.1016/S0140-6736(11)60756-3.
    Epub 2011 Jul 23.'
- PMID: '23907995'
  citation: 'Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano
    L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore
    M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM; Eteplirsen
    Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann
    Neurol. 2013 Nov;74(5):637-47. doi: 10.1002/ana.23982. Epub 2013 Sep 10.'
- PMID: '21428760'
  citation: 'Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans
    N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A,
    van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom
    JC. Systemic administration of PRO051 in Duchenne''s muscular dystrophy. N Engl
    J Med. 2011 Apr 21;364(16):1513-22. doi: 10.1056/NEJMoa1011367. Epub 2011 Mar
    23. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.'
- PMID: '18598348'
  citation: 'Kerkis I, Ambrosio CE, Kerkis A, Martins DS, Zucconi E, Fonseca SA, Cabral
    RM, Maranduba CM, Gaiad TP, Morini AC, Vieira NM, Brolio MP, Sant''Anna OA, Miglino
    MA, Zatz M. Early transplantation of human immature dental pulp stem cells from
    baby teeth to golden retriever muscular dystrophy (GRMD) dogs: Local or systemic?
    J Transl Med. 2008 Jul 3;6:35. doi: 10.1186/1479-5876-6-35.'
overall_contact_backup:
  first_name: 
  last_name: Cengiz Yakicier, Prof.Dr.
  middle_name: 
  phone_ext: 
  phone: 05362998743
  degrees: 
  email: cengiz.yakicier@asg.com.tr
completion_date:
  attributes:
    type: Anticipated
  value: November 2015
responsible_party: {}
firstreceived_results_date: 
is_section_801: 
detailed_description: {}
link: []
has_expanded_access: 'No'
id: NCT02285673
intervention:
- intervention_name: Umbilical Cord Mesenchymal Stem Cell
  other_name:
  - umbilical cord mesenchymal stem cells
  description: 
  arm_group_label:
  - Umbilical Cord Mesenchymal Stem Cell
  intervention_type: Biological
source: Acibadem University
eligibility:
  gender: Male
  maximum_age: 20 Years
  sampling_method: 
  minimum_age: 7 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

              - Patients with diagnosis of DMD that is proven clinically and genetically Age between
              7-20 Patients need partial respiratory support, during the day Patients have less than or
              equal to stage I NIH, Liver, renal and cardiac function Patients without cancer Patients
              without allergic disease Patients without bleeding diathesis,

              Exclusion Criteria:

              Patients need complete respiratory support Patients have more than to stage II NIH, Liver,
              renal and cardiac function Patients have bleeding diathesis and allergic disease
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date:
  attributes:
    type: Anticipated
  value: February 2015
last_injected: '2015-07-13T23:56:23.435Z'
intervention_browse: {}
target_duration: 
number_of_arms: '1'
start_date: November 2013
why_stopped: 
id_info:
  org_study_id: DMD-UC-MSC-1
  secondary_id: []
  nct_alias: []
  nct_id: NCT02285673
acronym: 
arm_group:
- description: 
  arm_group_label: Umbilical Cord Mesenchymal Stem Cell
  arm_group_type: Experimental
sponsors:
  collaborator: []
  lead_sponsor:
    agency: Acibadem University
    agency_class: Other
secondary_outcome: []
study_type: Interventional
biospec_retention: 
overall_status: Recruiting
primary_outcome:
- safety_issue: 'Yes'
  time_frame: up to 9 months
  description: 
  measure: Duchenne muscular dystrophy gene expression
overall_official: []
phase: Phase 1/Phase 2
location_countries:
  country:
  - Turkey
condition:
- Duchenne Muscular Dystrophy
clinical_results: {}
study_design: 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study,
  Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose:
  Treatment'
keyword:
- umbilical cord, mesenchymal stem cell
results_reference: []
oversight_info:
  has_dmc: 'No'
  authority:
  - 'Turkey: Ministry of Health'
number_of_groups: 
location:
- status: Recruiting
  contact_backup: {}
  facility:
    name: Acibadem Labcell
    address:
      city: Istanbul
      state: Uskudar
      zip: '34662'
      country: Turkey
  investigator: []
  contact:
    first_name: 
    last_name: Ercument Ovali, Prof. Dr.
    middle_name: 
    phone_ext: 
    phone: "+905325729174"
    degrees: 
    email: ercument.ovali@acibadem.com.tr
  geodata:
    latitude: 41.016667
    original: Istanbul, Uskudar
    longitude: 29.033333
    formatted: "Üsküdar/Istanbul, Turkey"
official_title: 'Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular
  Dystrophy: Phase 1/2 Study'
verification_date: November 2014
required_header:
  url: https://clinicaltrials.gov/show/NCT02285673
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact:
  first_name: 
  last_name: Ercument Ovali, Prof.Dr.
  middle_name: 
  phone_ext: 
  phone: "+905325729174"
  degrees: 
  email: ercument.ovali@acibademlabcell.com.tr
brief_title: Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular
  Dystrophy
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophy, Duchenne
brief_summary:
  textblock: |-
    Duchenne muscular dystrophy (DMD) is a genetic disorder caused by an absence of dystrophin
          and characterized by progressive muscle degeneration. There is no cure for DMD at present
          but, there are several strategies under-researched for treatment of DMD such as steroid
          treatment, gene theraphy, exon skipping, stop codon read through and gene repair, cell
          theraphy and theraphy with drug that help to produce utrophin protein.

          The aim of this study is investigate the eficacy of human umblical cord mesenchymal stem
          cells on DMD and understanding if wild type gene can be transfered to the patient.
enrollment:
  attributes:
    type: Anticipated
  value: '10'
lastchanged_date: November 6, 2014
